Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 34 (December 1), 2005: pp. 8646-8654
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.02.4646
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Publisher's Note
Right arrow Erratum (v24,p724)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burtness, B.
Right arrow Articles by Forastiere, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burtness, B.
Right arrow Articles by Forastiere, A. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

Barbara Burtness, Meredith A. Goldwasser, William Flood, Bassam Mattar, Arlene A. Forastiere

From the Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Department of Biostatistics, Harvard School of Public Health, Boston, MA; Division of Hematology/Oncology, Milton S. Hershey Medical Center, Hershey, PA; Cancer Center of Kansas, Wichita, KS; the Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD

Address reprint requests to Barbara Burtness, MD, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111; e-mail: barbara.burtness{at}fccc.edu

PURPOSE: Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck results in median progression-free survival (PFS) of 2 months. These cancers are rich in epidermal growth factor receptor (EGFR). We wished to determine whether the addition of cetuximab, which inhibits activation of EGFR, would improve PFS.

PATIENTS AND METHODS: Patients with recurrent/metastatic squamous cell carcinoma of the head and neck were randomly assigned to receive cisplatin every 4 weeks, with weekly cetuximab (arm A) or placebo (arm B). Tumor tissue was assayed for EGFR expression by immunohistochemistry. The primary end point was PFS. Secondary end points of interest were response rate, toxicity, overall survival, and correlation of EGFR with clinical end points.

RESULTS: There were 117 analyzable patients enrolled. Median PFS was 2.7 months for arm B and 4.2 months for arm A. The hazard ratio for progression of arm A to arm B was 0.78 (95% CI, 0.54 to 1.12). Median overall survival was 8.0 months for arm B and 9.2 months for arm A (P = .21). The hazard ratio for survival by skin toxicity in cetuximab-treated patients was 0.42 (95% CI, 0.21 to 0.86). Objective response rate was 26% for arm A and 10% for arm B (P = .03). Enhancement of response was greater for patients with EGFR staining present in less than 80% of cells.

CONCLUSION: Addition of cetuximab to cisplatin significantly improves response rate. There was a survival advantage for the development of rash. Progression-free and overall survival were not significantly improved by the addition of cetuximab in this study.

Supported in part by Public Health Service Grants No. CA23318, CA66636, CA21115, CA07190, and CA16116 from the National Cancer Institute, National Institutes of Health, and the United States Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, Orlando, FL, and the American Association for Cancer Research/National Cancer Institute/European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets in Cancer Therapy, November 17-21, 2003, Boston, MA.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Lorenzen, T. Schuster, R. Porschen, S.-E. Al-Batran, R. Hofheinz, P. Thuss-Patience, M. Moehler, P. Grabowski, D. Arnold, T. Greten, et al.
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
Ann. Onc., June 23, 2009; (2009) mdp069v1.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. J. Freeman, T. Bush, S. Ogbagabriel, B. Belmontes, T. Juan, C. Plewa, G. Van, C. Johnson, and R. Radinsky
Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor
Mol. Cancer Ther., June 1, 2009; 8(6): 1536 - 1546.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Schoder, M. Fury, N. Lee, and D. Kraus
PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 74S - 88S.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. Kiyota, M. Tahara, S. Kadowaki, N. Fuse, T. Doi, H. Minami, and A. Ohtsu
Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan
Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 225 - 230.
[Abstract] [Full Text] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
R. L. Barros Costa
Review Article: Targeted Therapy: Comprehensive Review
American Journal of Hospice and Palliative Medicine, April 1, 2009; 26(2): 137 - 146.
[Abstract] [PDF]

Home page
 J. Clin. Pathol.Home page
V Martin, L Mazzucchelli, and M Frattini
An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology
J. Clin. Pathol., April 1, 2009; 62(4): 314 - 324.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Y. Lai, P. Koppikar, S. M. Thomas, E. E. Childs, A. M. Egloff, R. R. Seethala, B. F. Branstetter, W. E. Gooding, A. Muthukrishnan, J. M. Mountz, et al.
Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms
J. Clin. Oncol., March 10, 2009; 27(8): 1235 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
T. YAMASHITA, S. SHINDEN, T. WATABE, and A. SHIOTANI
Outpatient Chemotherapy with S-1 for Recurrent Head and Neck Cancer
Anticancer Res, February 1, 2009; 29(2): 577 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
R. Czerninski, P. Amornphimoltham, V. Patel, A. A. Molinolo, and J. S. Gutkind
Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model
Cancer Prevention Research, January 1, 2009; 2(1): 27 - 36.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Gelbard, M. E. Kupferman, S. A. Jasser, W. Chen, A. K. El-Naggar, J. N. Myers, and E. Y. Hanna
An Orthotopic Murine Model of Sinonasal Malignancy
Clin. Cancer Res., November 15, 2008; 14(22): 7348 - 7357.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, S. Rottey, J. Erfan, D. Zabolotnyy, H.-R. Kienzer, D. Cupissol, et al.
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
N. Engl. J. Med., September 11, 2008; 359(11): 1116 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. I. Haddad and D. M. Shin
Recent Advances in Head and Neck Cancer
N. Engl. J. Med., September 11, 2008; 359(11): 1143 - 1154.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Psyrri, B. Egleston, E. Pectasides, P. Weinberger, Z. Yu, D. Kowalski, C. Sasaki, B. Haffty, D. Rimm, and B. Burtness
Correlates and Determinants of Nuclear Epidermal Growth Factor Receptor Content in an Oropharyngeal Cancer Tissue Microarray
Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1486 - 1492.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. L. Boehm, M. Sen, R. Seethala, W. E. Gooding, M. Freilino, S. M. Y. Wong, S. Wang, D. E. Johnson, and J. R. Grandis
Combined Targeting of Epidermal Growth Factor Receptor, Signal Transducer and Activator of Transcription-3, and Bcl-XL Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck
Mol. Pharmacol., June 1, 2008; 73(6): 1632 - 1642.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. A. Burtness, J. Manola, R. Axelrod, A. Argiris, and A. A. Forastiere
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
Ann. Onc., May 1, 2008; 19(5): 977 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Marur and A. A. Forastiere
Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
Mayo Clin. Proc., April 1, 2008; 83(4): 489 - 501.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Ciardiello and G. Tortora
EGFR Antagonists in Cancer Treatment
N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. R. Seethala, W. E. Gooding, P. N. Handler, B. Collins, Q. Zhang, J. M. Siegfried, and J. R. Grandis
Immunohistochemical Analysis of Phosphotyrosine Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor Autocrine Signaling Pathways in Head and Neck Cancers and Metastatic Lymph Nodes
Clin. Cancer Res., March 1, 2008; 14(5): 1303 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bernier, J Bonner, J. B. Vermorken, R.-J. Bensadoun, R. Dummer, J. Giralt, G. Kornek, A. Hartley, R. Mesia, C. Robert, et al.
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
Ann. Onc., January 1, 2008; 19(1): 142 - 149.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
N. Choong and E. Vokes
Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer
CA Cancer J Clin, January 1, 2008; 58(1): 32 - 53.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Gallerani, M. Ciriolo, C. Rossini, and F. Cavalli
Axillary Apocrine Carcinoma With Brain Metastases
J. Clin. Oncol., December 10, 2007; 25(35): 5655 - 5656.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Thomas, P. Rochaix, A. Benlyazid, J. Sarini, M. Rives, J. L. Lefebvre, B. C. Allal, F. Courbon, E. Chatelut, and J.-P. Delord
Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., December 1, 2007; 13(23): 7086 - 7092.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Langer, J. Harris, E. M. Horwitz, N. Nicolaou, M. Kies, W. Curran, S. Wong, and K. Ang
Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911
J. Clin. Oncol., October 20, 2007; 25(30): 4800 - 4805.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Janne, J. von Pawel, R. B. Cohen, L. Crino, C. A. Butts, S. S. Olson, I. A. Eiseman, A. A. Chiappori, B. Y. Yeap, P. F. Lenehan, et al.
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3936 - 3944.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. H. O'Neil, R. Allen, D. R. Spigel, T. E. Stinchcombe, D. T. Moore, J. D. Berlin, and R. M. Goldberg
High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History
J. Clin. Oncol., August 20, 2007; 25(24): 3644 - 3648.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Elser, L. L. Siu, E. Winquist, M. Agulnik, G. R. Pond, S. F. Chin, P. Francis, R. Cheiken, J. Elting, A. McNabola, et al.
Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma
J. Clin. Oncol., August 20, 2007; 25(24): 3766 - 3773.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Morgensztern and R. Govindan
Is There a Role for Cetuximab in Non Small Cell Lung Cancer?
Clin. Cancer Res., August 1, 2007; 13(15): 4602s - 4605s.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. V. Karamouzis, J. R. Grandis, and A. Argiris
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
JAMA, July 4, 2007; 298(1): 70 - 82.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Forastiere and B. A. Burtness
Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer--More Insights, but More Questions
J. Clin. Oncol., June 1, 2007; 25(16): 2152 - 2155.
[Full Text] [PDF]

Home page
 JCOHome page
J. B. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-Rubio, F. Rolland, R. Knecht, N. Amellal, A. Schueler, and J. Baselga
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy
J. Clin. Oncol., June 1, 2007; 25(16): 2171 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. L. Siu, D. Soulieres, E. X. Chen, G. R. Pond, S. F. Chin, P. Francis, L. Harvey, M. Klein, W. Zhang, J. Dancey, et al.
Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study
J. Clin. Oncol., June 1, 2007; 25(16): 2178 - 2183.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Agulnik, G. da Cunha Santos, D. Hedley, T. Nicklee, P. P. dos Reis, J. Ho, G. R. Pond, H. Chen, S. Chen, Y. Shyr, et al.
Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib
J. Clin. Oncol., June 1, 2007; 25(16): 2184 - 2190.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. J. Lynch Jr., E. S. Kim, B. Eaby, J. Garey, D. P. West, and M. E. Lacouture
Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
Oncologist, May 1, 2007; 12(5): 610 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Cruz, A Ocana, E Del Barco, and A Pandiella
Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
Ann. Onc., March 1, 2007; 18(3): 421 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Fracasso, H. Burris III, M. A. Arquette, R. Govindan, F. Gao, L. P. Wright, S. A. Goodner, F. A. Greco, S. F. Jones, N. Willcut, et al.
A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Clin. Cancer Res., February 1, 2007; 13(3): 986 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran
Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. R. Tan, D. F. Moore, M. Hidalgo, J. H. Doroshow, E. A. Poplin, S. Goodin, D. Mauro, and E. H. Rubin
Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors
Clin. Cancer Res., November 1, 2006; 12(21): 6517 - 6522.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Chung, K. Ely, L. McGavran, M. Varella-Garcia, J. Parker, N. Parker, C. Jarrett, J. Carter, B. A. Murphy, J. Netterville, et al.
Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas
J. Clin. Oncol., September 1, 2006; 24(25): 4170 - 4176.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. S. Chadha, T. Khoury, J. Yu, J. D. Black, J. F. Gibbs, B. W. Kuvshinoff, D. Tan, M. G. Brattain, and M. M. Javle
Activated Akt and Erk Expression and Survival After Surgery in Pancreatic Carcinoma
Ann. Surg. Oncol., July 1, 2006; 13(7): 933 - 939.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bourhis, F. Rivera, R. Mesia, A. Awada, L. Geoffrois, C. Borel, Y. Humblet, A. Lopez-Pousa, R. Hitt, M. E. Vega Villegas, et al.
Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 20, 2006; 24(18): 2866 - 2872.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. D. Colevas
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2644 - 2652.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E.W. Cohen
Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2659 - 2665.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
D. Vallbohmer, J. H. Peters, H. Kuramochi, D. Oh, D. Yang, D. Shimizu, S. R. DeMeester, J. A. Hagen, P. T. Chandrasoma, K. D. Danenberg, et al.
Molecular Determinants in Targeted Therapy for Esophageal Adenocarcinoma
Arch Surg, May 1, 2006; 141(5): 476 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Gray, J. Manola, S. Saxman, J. Wright, J. Dutcher, M. Atkins, M. Carducci, W. See, C. Sweeney, G. Liu, et al.
Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Clin. Cancer Res., April 1, 2006; 12(7): 1966 - 1969.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. A. Conley
Treatment of Advanced Head and Neck Cancer: What Lessons Have We Learned?
J. Clin. Oncol., March 1, 2006; 24(7): 1023 - 1025.
[Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, Y. B. Su, D. H. Kraus, S. L. Wolden, E. Lis, T. B. Aliff, A. J. Zahalsky, S. Lake, M. N. Needle, A. R. Shaha, et al.
Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm
J. Clin. Oncol., March 1, 2006; 24(7): 1072 - 1078.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. A Frieze and J. S McCune
Current Status of Cetuximab for the Treatment of Patients with Solid Tumors
Ann. Pharmacother., February 1, 2006; 40(2): 241 - 250.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online